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Dobutamine Stress Testing Revisited
I read with great interest the recently published study by Calnon et
al. (1), which analyzed the clinical outcome of patients who under-
went dobutamine stress single-photon emission computed tomogra-
phy (SPECT) Tc-99m-sestamibi imaging. Two aspects of this study
are rather intriguing, and deserve further examination.
First, the annual “hard” cardiac event rate in patients with
normal dobutamine SPECT studies was 2.3%. This is more than
twofold higher than previously published event rates after a normal
exercise stress perfusion study (1%). It is also substantially higher
than previously reported in other patients with normal dobutamine
SPECT. Previous studies, including a large series by Geleijnse et
al. (2), reported an annual event rate of 0.8% for hard events, and
2.5% for all cardiac events in patients with normal dobutamine
Tc-99m-sestamibi SPECT studies. As stated by the investigators
(1), some “probably normal” studies were grouped into the “normal
study” category, and neither attenuation correction nor gated
analyses were used in most studies. It is possible that these factors
may have affected observed event rates.
Second, the multivariate analysis identified the electrocardio-
gram (ECG) response and SPECT perfusion results as independent
predictors of cardiac events after accounting for clinical variables. As
a group, patients with abnormal ST-segment changes and normal
myocardial perfusion had a similar intermediate rate of events as did
those with perfusion defects but without abnormal ST-segment
changes on their ECG. This is a very interesting finding, and has the
potential for changing our common clinical practice.
It may be helpful to separate the two groups with intermediate
event rates and report the outcome separately for each group.
Commonly, patients with SPECT scans revealing no perfusion
abnormalities or ancillary findings suggestive of coronary artery
disease, but with ischemic ST-segment changes during dobut-
amine stress, are often classified as “normal.” Thus, it will be
particularly useful to know whether the outcome in this group
differed significantly from a subgroup of dobutamine stress patients
with normal ECG and normal perfusion. If, indeed, patients with
abnormal ST-segment changes but normal perfusion during do-
butamine stress testing have an intermediate event rate, it would be
interesting to know whether any significant clinical variables might
explain a relatively high event rate in this subset.
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REPLY
Our observation of a relatively high cardiac event rate in patients
with normal dobutamine Tc-99m-sestamibi single-photon emis-
sion computed tomography (SPECT) studies must be considered
in the context of the high intrinsic risk of the population referred
for dobutamine perfusion imaging at our institution (1). We
reserve dobutamine for patients who are unable to perform adequate
exercise and have contraindications to adenosine or dipyridamole
stress. Geleijnse et al. (2) used dobutamine more liberally (e.g.,
included patients without contraindications to vasodilator stress),
which might have contributed to the lower cardiac event rates
observed in patients with normal dobutamine Tc-99m-sestamibi
SPECT studies at their institution. Geleijnse et al. (2) assigned
patients with “equivocal defects” to the “normal scan” group, and
studies were interpreted without the use of electrocardiogram (ECG)-
gating or attenuation correction. It is therefore unlikely that these
technical factors were responsible for the higher cardiac event rates in
patients with normal dobutamine Tc-99m-sestamibi SPECT scans in
our study. We believe that the higher cardiac event rates reflect the
high intrinsic risk of the population referred for dobutamine perfusion
imaging at our institution. This conclusion is supported by the
significantly higher cardiac event rate in patients with abnormal
dobutamine Tc-99m-sestamibi SPECT studies (1) than in patients
with abnormal exercise Tc-99m-sestamibi SPECT studies (3).
We agree that the subgroup of patients (n  23) with
dobutamine-induced ST- depression and normal SPECT results is
of particular clinical interest. Absence of a perfusion defect could
have resulted from “balanced” myocardial ischemia due to diffuse
coronary disease without a normally perfused myocardial region,
though this phenomenon is rare and unlikely to have occurred in
all 23 patients. Only three total cardiac events were observed in this
subgroup (one cardiac death and two nonfatal myocardial infarc-
tions [MIs]), but the annual cardiac event rates were relatively high
owing to the small sample size (cardiac death and nonfatal MI
rates of 2.6% and 5.2%, respectively). These findings should be
confirmed in a larger group of patients before specific recommen-
dations are made regarding management of patients with
dobutamine-induced ST depression and normal SPECT images.
The larger subgroup of patients (n  129) with normal ECG
responses but abnormal SPECT images had a high rate of cardiac
events (10 cardiac deaths [4.5%/year] and 8 nonfatal MIs [3.6%/
year]). This subgroup of patients should be considered at high risk
for cardiac events and should be managed accordingly.
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Atrial Fibrillation-Induced
Gap Junctional Remodeling
With great interest we have read the study by Polontchouk et al.
(1) on changes in the distribution of gap junctions—clusters of
intercellular channels that allow action potentials to propagate
from one cardiomyocyte to another—during atrial fibrillation (AF).
In atrial tissue from chronic AF patients, the researchers observed a
2.7-fold increase in connexin40 (Cx40) gap junction protein while
levels of Cx43 had not changed. For both connexins, a partial
redistribution from polar to lateral cell membranes was observed.
Possible biophysical implications were tested by determination of
changes in anisotropy—ratio of longitudinal (VL) and transverse (VT)
conduction velocities—in a rat model of pacing-induced AF (24 h at
10 Hz) showing similar changes in Cx43 distribution.
First, we would like to comment on the immunohistochemical
analyses performed. The antibody against Cx40 was said to
recognize a 40-kDa protein in adult rat ventricular cardiomyocytes.
Because these cells do not express Cx40, this suggests cross-
reactivity with Cx43. Immunohistochemical staining of human
tissue is often hampered by high levels of autofluorescence of
extracellular matrix components (elastin). In this context only
some of the blue arrows in their Figure 3 (1) point at lateral
connexin labeling, suggesting “connexin lateralization” to be
smaller than indicated.
Second, the investigators speculate that the observed connexin
redistribution may contribute to the formation of an arrhythmo-
genic substrate for AF, based on their finding in the rat model of
a 40-fold increase in lateral Cx43 staining from 1.5% to 61% in
parallel to a change in anisotropy from 3.6  0.5 to 2.4  0.1
(from text; for the same set of data, their Figure 6 shows 3.8  0.8
and 1.9  0.2, respectively). However, lateral Cx43 staining in rat
atrial tissue kept at sinus rate for 24 h increased 6-fold (from 1.5%
to 9.0%; as shown in their Figure 5) without any change in
anisotropy. Both from this observation and from model studies on
cardiac action potential conduction (e.g., by Kle´ber [2], Spach et
al. [3], and Jongsma and Wilders [4]) we believe the functional
significance of the much smaller increase in connexin staining in
human atrial tissue (from 5% to 16%, and from 9% to 22% for
Cx43 and Cx40, respectively) might be minimal.
In the goat we found AF-induced inhomogeneities in the atrial
distribution pattern of Cx40 consisting of small (0.15 to 0.6 mm
diameter) areas of low to almost zero density (5). We hypothesize
that this phenomenon, rather then “lateralization” of gap junc-
tions, forms a likely basis for the generation of micro-heterogeneity
(or micro-dispersion) in conduction velocity and might support
microreentry, which could lead to sustained AF.
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REPLY
In our study (1) we have shown changes in the expression and
localization of the gap junction proteins connexin40 (Cx40) and
connexin43 (Cx43) in patients suffering from chronic atrial fibril-
lation (AF). We found increased Cx40 and unchanged Cx43
expression. Moreover, we observed lateralizations of both connex-
ins that were no longer confined to the cellular poles. In a rat
model of pacing-induced AF, lateralization was also found along
with a change in anisotropy.
Regarding the communication from van der Velden and col-
leagues, there is pobably some misunderstanding: It is stated
clearly in our report that we produced a polyclonal antibody against
a polypeptide comprising amino acids 231–330 of rat Cx40. There
is no putative amino acid sequence homologous to Cx43.
This antibody did not show crossreactivity with other connex-
ins. This was tested in Western blots from HeLa cells transfected
with either Cx43 or Cx40. Immunocytochemistry demonstrated
that Cx40 staining differs from Cx43 staining. In rat and mice, we
did not see any Cx40 staining in the smooth muscle cells (SMC)
of aortae, whereas Cx43 antibodies recognized Cx43 in SMC. The
specificity of the antibody has also been shown in rat kidney (2).
When freshly isolated ventricular cardiomyocytes from two-
month-old rats were cultured, redifferentiation was found with
differential time-dependent changes in connexin expression and
phosphorylation and no crossreactivity between Cx40 and Cx43.
Regarding the immunostainings, there is autofluorescence from
connective tissue. However, this is typical for this kind of human
tissue. It is difficult to differentiate between connective tissue and
specific staining (especially in the reproductions), but it is possible
because the connective tissue shows typical thin, curly, fluorescent
lines. Moreover, there is yellowish fluorescence from lipofuscine,
which also disturbs. Thus, although we agree that it is difficult to
evaluate, we have seen enhanced presence of specific immunoflu-
orescence at the lateral sides of the cells in AF patients.
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